Vical’s Vaxfectin adjuvant boosts immune response of DNA-based vaccines against cancer

Vical Incorporated announced today that the company’s Vaxfectin® adjuvant has significantly boosted the immune response of -based vaccines against a range of pathogens and in preclinical models from rodents to non-human primates. Vaxfectin® has demonstrated similar effects with - and peptide-based vaccines in preclinical models.


Read more

Related posts

Leave a Reply